|
|
Volumn 118, Issue 9, 2005, Pages 1055-1056
|
|
The Vioxx debacle revisited [8] (multiple letters)
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
CELECOXIB;
CYCLOOXYGENASE 2 INHIBITOR;
IBUPROFEN;
NONSTEROID ANTIINFLAMMATORY AGENT;
ROFECOXIB;
ANALGESIA;
CARDIOTOXICITY;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
COMPARATIVE STUDY;
COST EFFECTIVENESS ANALYSIS;
DRUG APPROVAL;
DRUG COST;
DRUG EFFECT;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG MONITORING;
DRUG SAFETY;
DRUG SCREENING;
DRUG TOLERABILITY;
DRUG USE;
GASTROINTESTINAL DISEASE;
GASTROINTESTINAL SYMPTOM;
GASTROINTESTINAL TOXICITY;
HEART INFARCTION;
HIGH RISK PATIENT;
HUMAN;
KIDNEY DISEASE;
LAW SUIT;
LETTER;
MEDICAL LITERATURE;
MEDICAL PRACTICE;
MIGRAINE;
OSTEOARTHRITIS;
PAIN;
PHYSICIAN;
POLITICAL SYSTEM;
PRESCRIPTION;
PRIORITY JOURNAL;
PROFIT;
|
|
EID: 24744462673
PISSN: 00029343
EISSN: None
Source Type: Journal
DOI: 10.1016/j.amjmed.2005.04.020 Document Type: Letter |
|
Times cited : (3)
|
|
References (6)
|
